Revolution Medicines, Inc. (RVMD)

39.36 +0.17 (+0.43%) 市場開市。 截至 12:12PM EDT。

Revolution Medicines, Inc.

700 Saginaw Drive
Redwood City, CA 94063
United States
650 481 6801
https://www.revmed.com

版塊: Healthcare
行業: Biotechnology
全職員工: 378

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Mark A. Goldsmith Ph.D.	CEO, President & Chairman	1.12M	2.85M	1962
Mr. Jack Anders	Chief Financial Officer	665.28k	1.02M	1977
Ms. Margaret A. Horn J.D.	Chief Operating Officer	811.08k	1.68M	1963
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.	President of Research & Development	812.17k	無	1961
Ms. Xiaolin Wang	Executive Vice President of Development	633.74k	無	1971
Dr. Martin D. Burke M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	無	無	無
Dr. Michael A. Fischbach Ph.D.	Academic Co-Founder & Member of Scientific Advisory Board	無	無	1981
Dr. Kevan M. Shokat Ph.D.	Academic Co-Founder & Member of Scientific Advisory Board	無	無	無
Mr. Walter Reiher Ph.D.	Chief Information Officer	無	無	無
Ms. Jan Smith Ph.D.	Chief Scientific Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

公司管治

截至 2024年5月1日 止，Revolution Medicines, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：8；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。